Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs
| Autor: | A. Griffin, Kathleen O'Connell, Maurine J. Thomson, Elizabeth J. Morgan |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Vincristine medicine.medical_specialty 040301 veterinary sciences Prednisolone medicine.medical_treatment Lymphoma T-Cell Procarbazine Gastroenterology Disease-Free Survival 0403 veterinary science 03 medical and health sciences Dogs 0302 clinical medicine Lomustine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Animals T-cell lymphoma Dog Diseases Progression-free survival Chemotherapy Canine Lymphoma General Veterinary business.industry 04 agricultural and veterinary sciences medicine.disease Survival Analysis 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | Veterinary and Comparative Oncology. 16:622-629 |
| ISSN: | 1476-5810 |
| Popis: | Canine T cell lymphoma has previously been found to be a poor prognostic indicator compared with its B cell counterpart. The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma. There have been several studies investigating alternative protocols for T cell lymphoma. This study investigated the use of a modified lomustine, vincristine, procarbazine and prednisolone protocol as a first line treatment in 35 dogs with T Cell lymphoma. Median progression free survival (PFS) time for all 35 dogs was 431 days with a 6-month, 1-year, 2-year, and 3-year PFS of 69%, 54%, 29%, and 12%. Median survival time (MST) was 507 days. Twenty-nine dogs attained a complete response and had a median PFS time of 509 days. Thirty dogs experienced adverse events during the protocol, with 73% of these being grade 1 or 2. This protocol has shown increased median PFS time and MST compared with previous studies and suggests its use as a first line chemotherapy protocol against canine T cell lymphoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |